PubMed Health⌕ Search

Biomedical subjects

Xia Liu

Publications and source records attributed to Xia Liu.

2 recordsLinked to original sources
PubMed2026

Phylogenetic and Functional Analyses of Wheat TaMAN Genes Responding to Salinity and Pathogens.

Endo-β-1,4-mannanases (MANs) are glycoside hydrolase family 5 (GH5) enzymes that degrade cell wall mannan polysaccharides and participate in plant growth and stress adaptation. This gene family has not been systematically characterized in common wheat (Triticum aestivum L.). Here, we identified 24 TaMAN genes (TaMAN1-TaMAN24) genome-wide and analyzed their phylogeny, gene structures, chromosomal distribution, synteny, and promoter cis-acting elements. Expression profiles under biotic and abiotic stresses were investigated using public databases, salt-stress RNA-seq, and RT-qPCR. TaMAN proteins (386-475 aa) were mainly predicted to localize in the extracellular space. Phylogenetic analysis divided them into three groups, with Groups II and III representing monocot-specific expansions. Family expansion was driven primarily by whole-genome duplication, supplemented by tandem duplication on homoeologous group 6. Promoters were enriched in hormone- and stress-responsive cis-acting elements (ABRE, as-1/CGTCA-motif, W box). TaMAN1, TaMAN5, TaMAN8, TaMAN9, TaMAN16 and TaMAN19 were significantly induced by powdery mildew, while TaMAN3, TaMAN4 and TaMAN19-TaMAN22 rapidly responded to salt stress. This study provides candidate genes for disease-resistant and salt-tolerant wheat breeding.

TaMAN gene↗
PubMed2026

Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.

To elucidate the molecular basis underlying differential responses and resistance to ibrutinib in Waldenström macroglobulinemia (WM), we conducted a prospective phase 2 trial of ibrutinib monotherapy in treatment-naïve patients. A total of 74 sequential bone marrow (BM) aspirates from 17 patients, collected from baseline through 48 treatment cycles, were profiled using single-cell multiomics. BM cells were segregated primarily into B-cell/plasma cell and T-cell compartments. Longitudinal clonal tracking of malignant B cells/plasma cells identified 3 distinct evolutionary patterns: evolution (early clone contraction with late clone expansion and increasing genomic complexity), devolution (early clone expansion with late clone contraction and genomic simplification), and no evolution (stable clonal architecture). The evolution pattern was strongly associated with disease progression, whereas devolution correlated with durable clinical response. Transcriptomic profiling of resistant clones enabled development and validation of the Waldenström ibrutinib prediction (WIP) score, which predicted treatment response at baseline. Within the WIP signature, LYN emerged as a key regulator; LYN knockdown or inhibition significantly increased WM cell sensitivity to ibrutinib, suggesting a rational combination strategy. In parallel, GZMB+ CD8+ effector-memory T cells expanded after treatment in patients with progressive disease and coexisted with tumor evolution. These cells exhibited persistently impaired cytotoxic programs (eg, GNLY), a dedifferentiated memory-like state, elevated PDCD1 expression, and reduced T-cell receptor diversity. Together, this study provides, to our knowledge, the first single-cell framework of tumor clonal evolution and T-cell dysfunction under ibrutinib in WM, introduces the WIP score as a predictive biomarker for treatment response, and identifies actionable tumor-intrinsic and immune mechanisms driving resistance. This trial was registered at www.ClinicalTrials.gov as NCT02604511.

Aged↗